|Bid||58.60 x 1000|
|Ask||59.00 x 800|
|Day's Range||58.27 - 59.72|
|52 Week Range||43.51 - 72.41|
|Beta (3Y Monthly)||1.46|
|PE Ratio (TTM)||120.80|
|Earnings Date||Feb 20, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||58.24|
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Shares of NuVasive, Inc. (NASDAQ: NUVA ) spiked after the Financial Times named the company as a potential acquisition target. A deal seems unlikely and, even if a bid is received, there is little opportunity ...
FT premium subscribers can click here to receive Due Diligence every day by email. The Due Diligence Forum is our new membership-based community that takes you deeper into the conversation on the major issues in corporate finance.
First reported by the Financial Times late Friday, NuVasive shares jumped as much as 18% on the Nasdaq Stock Exchange in after-hours trading. Citing "people with direct knowledge of the talks," the Financial Times noted that discussions between the companies were ongoing and that no definitive deal had been reached. London-based Smith & Nephew produces a wide range of medical equipment and products, including "advanced wound management products" and orthopedic reconstruction devices.
NuVasive stock popped Monday on a report Smith & Nephew could be considering buying it for about $3 billion. NuVasive stock made double-digit percentage gains in high volume on the news.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we'll look at NuVasive, Inc. (NASDAQ:NUVA)Read More...
NuVasive stock was on the rise Monday following news of a potential takeover from Smith & Nephew (NYSE:SNN).Source: Shutterstock The recent NuVasive (NASDAQ:NUVA) news claims that Smith & Nephew is looking to pick the company up for a price of $3 billion. This information comes from unnamed sources that are reportedly close to the takeover talks.According to these anonymous sources, the talks between NuVasive and Smith & Nephew are still ongoing and there still isn't a final agreement for the companies. As such, it is possible that the deal may not go on to reach completion, reports TheStreet.com.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNuVasive is the developer of treatments for chronic back pain and other issues with the spine. It fixes these problems with a type of minimally invasive surgery called Maximum Access Surgery. This only requires a small incision, about one inch to two inches, on the back.Smith & Nephew is a multinational l medical equipment manufacturing company. It headquarters is based out of London. The company has been around since 1856 and trades on the New York Stock Exchange, as well as the London Stock Exchange. * 10 Best Dividend Stocks to Buy for the Next 10 Months News about a possible takeover of NUVA really sent NuVasive stock soaring on Monday. The stock was up 15% as of Monday morning. However, this same news saw SNN stock dropping today. Smith & Nephew stock was down 4% as of noon Monday, but it is still up 10% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Fundamentally Sound Dividend Stocks to Buy * 5 Reasons Reeling FAANG Stocks Won't Deliver Big Returns * 3 Reasons Canopy Growth Could Burn You As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post NuVasive Stock Shoots Higher on Takeover Talk appeared first on InvestorPlace.
NuVasive share rose 11 percent to $54.85 at 9:57 a.m. in New York, after a report Friday in the Financial Times on the possible interest from the U.K. company. Smith & Nephew recently signaled its readiness to pursue a bigger deal, with Chief Executive Officer Namal Nawana saying last week the company wants to play in more areas of medical devices. The market questioned the rationale of buying NuVasive, however.
Alphatec Holdings, Inc. (“ATEC” or “the Company”) (ATEC) today announced several favorable developments in its ongoing patent litigation with NuVasive, Inc. (NUVA). “We are extremely pleased with the many legal successes that we have seen to date in this lawsuit, including the Court’s entry of the stay,” said Pat Miles, ATEC’s Chairman and Chief Executive Officer.
U.S. stock futures rose on Monday, Feb. 11, and global stocks traded cautiously higher as investors eyed progress in this week's renewed U.S.-China trade talks. U.S. Treasury Secretary Steven Mnuchin and Trade Representative Robert Lighthizer arrived in Beijing for trade talks Sunday that will focus on structural reforms and intellectual property protections in the world's second-largest economy. With that in mind, investors also will watch for any mention of risks from China tariffs from a host of retail-focused earnings this week, the final major round of reporting for the December quarter.
When contacted by Reuters, Smith & Nephew and NuVasive said they do not comment on market speculation. The exact terms of any talks could not be learned, and the discussions may still fall apart, the FT reported. The acquisition would mark the first major move by Smith & Nephew Chief Executive Namal Nawana.
Britain's Smith & Nephew Plc has held talks to buy U.S. medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks. When contacted by Reuters, Smith & Nephew and NuVasive said they do not comment on market speculation. The exact terms of any talks could not be learned, and the discussions may still fall apart, the FT reported.
NuVasive Inc NASDAQ/NGS:NUVAView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for NUVA with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding NUVA totaled $920 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
, a maker of medical instruments used in spinal surgery, in a deal that would be worth more than $3bn and mark the largest acquisition by the British medical devices group, people with direct knowledge of the talks said. The exact terms of any discussions could not be learned and talks between the two sides may fall apart, these people said. It is possible that the revelation of the talks may lead the discussions to end.
SAN DIEGO, Jan. 29, 2019 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company will release its fourth quarter and full year 2018 earnings results on Wednesday, Feb. 20, 2019 after the close of the market. NuVasive will hold a conference call on Wednesday, Feb. 20, 2019, at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the fourth quarter and full year 2018. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers.
Tamarack Capital Management is a hedge fund that was founded by Mr. Justin John Ferayorni, its current Chief Investment Officer and Portfolio Manager. Before deciding to start his own firm, Mr. Ferayorni built up serious experience in investing, working as a Healthcare Analyst and Portfolio Manager, and later own as a Director of Research at […]
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
On January 9, Globus Medical (GMED) was trading at a stock price of $43.79, which is an ~9.91% rise from its closing price of $39.84 on January 8. On January 4, Globus Medical’s stock price rose ~5.04% to $40.00 from its close of $38.08 on January 3. On January 3, the company hit its 52-week low of $38.01.
SAN DIEGO, Jan. 7, 2019 /PRNewswire/ -- NuVasive, Inc. (NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced preliminary unaudited revenue results for the fourth quarter and full year 2018. The Company expects fourth quarter 2018 revenue to be approximately $288 million and full year 2018 revenue to be approximately $1,102 million. NuVasive preliminary revenue results for full year 2018 reflect approximately 7% growth on a reported and constant currency basis, compared to revenue of $1,027 million for full year 2017.